Authors
Francesco Prattichizzo, Angelica Giuliani, Jacopo Sabbatinelli, Giulia Matacchione, Deborah Ramini, Anna Rita Bonfigli, Maria Rita Rippo, Paola de Candia, Antonio Domenico Procopio, Fabiola Olivieri, Antonio Ceriello
Publication date
2020/9
Journal
Diabetes, Obesity and Metabolism
Volume
22
Issue
9
Pages
1696-1700
Publisher
Blackwell Publishing Ltd
Description
Residual inflammatory risk (RIR) is defined as persistent circulating levels of high sensitivity C‐reactive protein (hs‐CRP) >2 mg/L despite an optimal (<70 mg/dL) control of LDL‐cholesterol (LDL‐C) and represents an emerging risk factor for the development of cardiovascular events in patients at high risk of atherosclerosis. Sparse data are available regarding the prevalence of RIR in patients with type 2 diabetes (T2D) and the clinical variables associated with hs‐CRP elevation. Here, we report data from a well‐characterized cohort of patients with T2D (n = 511) stratified for statins use, LDL‐C goal attainment and prevalent T2D complications. Statins use and having at‐target LDL‐C partially affect the number of patients with inflammatory risk when compared with the whole T2D population, with an RIR prevalence of 39.2%. Among the spectra of complications, only patients with nephropathy had a higher …
Total citations
20202021202220232024317798
Scholar articles
F Prattichizzo, A Giuliani, J Sabbatinelli, G Matacchione… - Diabetes, Obesity and Metabolism, 2020